Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab
- Development stage
- Phase 3
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Hepatic Arterial Infusion
01
Overview
This refers to a specific clinical trial regimen evaluated at The University of Texas M.D. Anderson Cancer Center for the treatment of advanced solid tumors with liver metastases. The protocol utilizes a localized delivery method known as hepatic arterial infusion (HAI) for oxaliplatin, a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit replication. This targeted delivery to the liver is combined with a systemic chemotherapy backbone consisting of 5-fluorouracil (5-FU), leucovorin, and the anti-VEGF monoclonal antibody bevacizumab. Depending on the patient's K-RAS mutational status, the anti-EGFR antibody cetuximab may also be included. The regimen is designed to maximize the concentration of chemotherapy reaching liver tumors while utilizing systemic agents to address potential extrahepatic disease.
- Other names
- HAI Oxaliplatin combination therapyHepatic Arterial Infusion of Oxaliplatin with systemic chemotherapy
02
Targets
DNATS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab.